Illumina Awarded $26.7m In Patent Row
Executive Summary
The verdict resolves an intellectual property dispute in which Illumina alleged Ariosa was violating Illumina's patents on prenatal genetic testing technology.
You may also be interested in...
One in the eye for Illumina as Roche buys prenatal test maker
Roche has acquired Ariosa Diagnostics, a privately-held US developer of blood tests used to detect Down syndrome and genetic abnormalities in the foetus.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.